Phages can be engineered to selectively delete virulence genes or to eliminate antibiotic-resistant bacteria associated with CRC by utilizing CRISPR-Cas3 or CRISPR-Cas9 technologies. This evidence concerns the gene EFS and colorectal carcinoma.